Articles On Proteomics International Laboratories (ASX:PIQ)

Around 1 million residents of some inner-Sydney suburbs are to stay at home until next Friday, after the latest government-imposed lockdown. The restrictions will begin at midnight today, and last until midnight on Friday, July 2. To market...

Proteomics International Laboratories says independent research on its “ground-breaking” PromarkerD test for diagnosis of kidney disease in diabetes sufferers suggests the test could improve quality of care and save US care services payers...

Wall Street climbs on Biden stimulus All three major US benchmarks rose on Thursday, as President Biden announced a US$579 billion stimulus. The Dow Jones rose by 0.95%, S&P 500 by 0.58%, and tech-heavy Nasdaq hit another record, rising...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week As we appro...

Proteomics International Laboratories (ASX:PIQ) has announced the expansion of its executive team with the appointments of Vik Malik as its new chief commercialisation officer (CCO) and Jacqueline Gray as its new chief financial off...

Ask a Fund Manager The Motley Fool chats with fund managers so that you can get an insight into how the professionals think. In Part 2 of this edition, Kardinia Capital’s portfolio manager Kristiaan Rehder reveals 2 small-cap ASX shares wi...

Summary Oncology firm Telix Pharmaceuticals has entered into an exclusive commercial distribution agreement to distribute its product in the German market. Proteomics has secured a significant contract for pharmacokinetic testing, whil...

Medical technology group, Proteomics International Laboratories has picked up an analytical services contract in pharmacokinetic testing worth $243,000 with leading clinical trial contract research organisation, Avance Clinical. Perth-based...

A series of ASX announcements has attracted investors to the biotech sector today, lifting the share prices of some of its players. The buying frenzy has also lifted the broader health sector by as high as 1 per cent earlier today, but is c...

Summary Telix Pharmaceuticals signs distribution agreement with Germany based company Proteomics International bags new pharmacokinetic testing contract com accomplishes A$428 million institutional entitlement offer Citi hikes PT for...

US and European stock markets down to start the week All major indices in US and Europe were down on Monday, after Covid cases spiked in some parts of the world. The Dow Jones was down 0.16%, S&P 500 fell 0.25%, and tech heavy NASDAQ dr...

Medical technology group, Proteomics International Laboratories says an economic health benefit study suggests its PromarkerD test for diabetic kidney disease has the potential to save Americans suffering from type 2 diabetes billions of do...

Sell-off on Wall Street after inflation rose to highest since 2009 All major indices in US tumbled after US consumer price increased by 0.8% in April, climbing by the most since 2009 and topping estimates. The steeper than expected inflatio...

After flying 5% higher this morning, it was downhill all the way for the Proteomics International Laboratories Ltd (ASX: PIQ) share price today. At the market close today, shares in the medical technology company were right back where they...

Proteomics International Laboratories has received an ISO 13485 certification, which it describes as the most widely used international standard for quality management systems in the manufacture of medical devices. It says the certification...

ASX-listed medical technology company, Proteomics International Laboratories’ coffers have been further boosted by a $1.1 million research and development tax rebate following a recent successful capital raise of $6 million.

ASX-listed medical technology company, Proteomics International Laboratories, has locked away $6m in cash via a heavily oversubscribed placement to UK-based and local institutions and other sophisticated investors, to progress the marketing...

Proteomics International Laboratories (ASX:PIQ) has announced it has signed a distribution licensing agreement for the immunoassay version of the PromarkerD predictive test for diabetic kidney disease.

ASX-listed medical technology company, Proteomics International Laboratories, has entered into an agreement with Medical Horizons that will see the Italy-based group distribute the easy-to-use immunoassay version of Proteomics’ PromarkerD p...

Australian company Proteomics International (ASX:PIQ) says it has secured patents for PromarkerD, a low cost, high throughput predictive test for diabetic kidney disease, in Brazil and Canada.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Towards th...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Clinical t...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Clinical t...

Medical technology company Proteomics International Laboratories (ASX: PIQ) announced that a global multi-centre study of 3,000 people has confirmed the effectiveness of PromarkerD as a predictive test for diabetic kidney disease. The colla...

Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics, has secured CE Mark registration for its PromarkerD Immunoassay kit as an IVD medical device (in vitro diagnostic). PromarkerD (IA) forms part of the...

Proteomics International Laboratories (PIQ) has secured CE Mark registration for the PromarkerD Hub The PromarkerD Hub is a software tool used to calculate the risk of kidney disease in patients with type 2 diabetes Proteomics will now p...

Orthocell (ASX:OCC) has found a new use for its CelGro tech – anterior cruciate ligament (ACL) injuries. The ACL is a major stabilising ligament in the knee. Once it is ruptured, it cannot be healed it must be replaced and recovery takes se...

Proteomics International Laboratories (ASX: PIQ) has embarked on a European commercialisation campaign following the launch of PromarkerD – its predictive diagnostic test for diabetic kidney disease – in Spain. The Spanish launch marks the...

Biotech company Mesoblast (ASX:MSB) has entered into a strategic partnership to develop and commercialise a stem cell treatment for chronic lower back pain. As part of the deal, Mesoblast said it could receive up to $150m ($218.6m) in up-fr...

Concurrently, TGA regulatory approval granted for PromarkerD software as an in vitro diagnostic for export use.

Australian healthcare industry challenges include an ageing population, increased rate of chronic diseases, emergence and integration of new technologies, etc. Some important Australian companies, which are working on integrating ‘SaaS’ mod...

Australia’s cannabis industry continues to edge forward under the watchful eye of regulators. For now, it’s the Office of Drug Control’s world — and domestic cannabis companies just live in it. Scroll down for more ASX cannabis news >&gt...

Perth-based Proteomics International Laboratories (ASX:PIQ) says it has been invited to feature on the American Diabetes Association TV News Network during the ADA 79th Scientific Sessions conference in San Francisco.